PRNewsWire
04 Jun 2026, 06:30 UTC · 2h ago
AbolerIS Pharma Presents New Data Supporting CD45RC as a Novel Therapeutic Target and Potential Biomarker in Sjögren's Disease at EULAR 2026
Search tags
PRNewsWire
04 Jun 2026, 06:30 UTC · 2h ago
Search tags
Story key points
3 claims · impact-rated
AbolerIS Pharma presented data showing a strong correlation between CD45RC expression and lymphocytic infiltration in Sjögren's disease salivary glands. — Provides biological proof-of-concept for CD45RC as a viable therapeutic target and biomarker, increasing the probability of success for their drug pipeline.
+0.60CD45RC expression was detected in early-stage 'pre-focus' lesions, suggesting the potential for early intervention in Sjögren's disease. — Expands the addressable patient population and clinical utility of the therapy to an earlier stage of the disease where options are currently limited.
+0.40The company's lead antibody, ABO21009, is currently in a Phase I study evaluating safety and pharmacodynamics in healthy volunteers and RA patients. — Confirms the asset is in early clinical development, though Phase I is a standard safety hurdle rather than a primary value inflection point.
+0.20Ticker attribution
Continue reading
6 related stories
Model heads
No ticker sentiment head found.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Browse live screeningsImpact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
PRNewsWire
1d ago
